224 related articles for article (PubMed ID: 25167802)
1. The role of the CpG island methylator phenotype on survival outcome in colon cancer.
Kang KJ; Min BH; Ryu KJ; Kim KM; Chang DK; Kim JJ; Rhee JC; Kim YH
Gut Liver; 2015 Mar; 9(2):202-7. PubMed ID: 25167802
[TBL] [Abstract][Full Text] [Related]
2. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
[TBL] [Abstract][Full Text] [Related]
3. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
Ogino S; Nosho K; Kirkner GJ; Kawasaki T; Meyerhardt JA; Loda M; Giovannucci EL; Fuchs CS
Gut; 2009 Jan; 58(1):90-6. PubMed ID: 18832519
[TBL] [Abstract][Full Text] [Related]
4. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
[TBL] [Abstract][Full Text] [Related]
5. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
[TBL] [Abstract][Full Text] [Related]
6. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.
Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S
PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263
[TBL] [Abstract][Full Text] [Related]
8. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
9. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.
Bae JM; Kim JH; Cho NY; Kim TY; Kang GH
Br J Cancer; 2013 Aug; 109(4):1004-12. PubMed ID: 23900220
[TBL] [Abstract][Full Text] [Related]
11. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Nosho K; Shima K; Irahara N; Kure S; Firestein R; Baba Y; Toyoda S; Chen L; Hazra A; Giovannucci EL; Fuchs CS; Ogino S
Mod Pathol; 2009 Jul; 22(7):922-32. PubMed ID: 19430421
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
[TBL] [Abstract][Full Text] [Related]
13. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
[TBL] [Abstract][Full Text] [Related]
14. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.
Nosho K; Shima K; Irahara N; Kure S; Baba Y; Kirkner GJ; Chen L; Gokhale S; Hazra A; Spiegelman D; Giovannucci EL; Jaenisch R; Fuchs CS; Ogino S
Clin Cancer Res; 2009 Jun; 15(11):3663-71. PubMed ID: 19470733
[TBL] [Abstract][Full Text] [Related]
15. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
Baba Y; Nosho K; Shima K; Goessling W; Chan AT; Ng K; Chan JA; Giovannucci EL; Fuchs CS; Ogino S
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):822-31. PubMed ID: 20200425
[TBL] [Abstract][Full Text] [Related]
16. No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
Jia M; Jansen L; Walter V; Tagscherer K; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
Br J Cancer; 2016 Nov; 115(11):1359-1366. PubMed ID: 27811854
[TBL] [Abstract][Full Text] [Related]
17. IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53.
Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS; Ogino S
Neoplasia; 2007 Dec; 9(12):1091-8. PubMed ID: 18084616
[TBL] [Abstract][Full Text] [Related]
18. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Ogino S; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS
Int J Cancer; 2008 Jun; 122(12):2767-73. PubMed ID: 18366060
[TBL] [Abstract][Full Text] [Related]
19. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.
Vedeld HM; Merok M; Jeanmougin M; Danielsen SA; Honne H; Presthus GK; Svindland A; Sjo OH; Hektoen M; Eknaes M; Nesbakken A; Lothe RA; Lind GE
Int J Cancer; 2017 Sep; 141(5):967-976. PubMed ID: 28542846
[TBL] [Abstract][Full Text] [Related]
20. CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer.
Chen KH; Lin LI; Tseng LH; Lin YL; Liau JY; Tsai JH; Liang JT; Lin BR; Cheng AL; Yeh KH
Oncology; 2019; 96(3):156-163. PubMed ID: 30540994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
